npj Breast Cancer · 2017 · 58 citations · 28 references
MedicineOncologyPharmacologyBreast OncologyChemotherapyMolecular OncologyAdjuvant TherapyBreast Cancer OncologyChemotherapy Toxicity ManagementMalignant NeoplasmsNeoadjuvant ChemotherapyNeoadjuvant TherapyBrca MutationsBreast Cancer ChemotherapyFeasibility Study DesignNeoadjuvant Taxane-based TherapyPost-neoadjuvant TherapyTaxane ChemotherapyTaxane-based ChemotherapyTumor Volume Measurement
Abstract This study was undertaken to determine the feasibility of enrolling breast cancer patients on a single-agent-targeted therapy trial before neoadjuvant chemotherapy. Specifically, we evaluated talazoparib in patients harboring a deleterious BRCA mutation (BRCA+). Patients with a germline BRCA mutation and ≥1 cm, HER2-negative primary tumors were eligible. Study participants underwent a pretreatment biopsy, 2 months of talazoparib, off-study core biopsy, anthracycline, and taxane-based chemotherapy ± carboplatin, followed by surgery. Volumetric changes in tumor size were determined by ultrasound at 1 and 2 months of therapy. Success was defined as 20 patients accrued within 2 years and <33% experienced a grade 4 toxicity. The study was stopped early after 13 patients ( BRCA 1 + n = 10; BRCA 2 + n = 3) were accrued within 8 months with no grade 4 toxicities and only one patient requiring dose reduction due to grade 3 neutropenia. The median age was 40 years (range 25–55) and clinical stage included I ( n = 2), II ( n = 9), and III ( n = 2). Most tumors ( n = 9) were hormone receptor-negative, and one of these was metaplastic. Decreases in tumor volume occurred in all patients following 2 months of talazoparib; the median was 88% (range 30–98%). Common toxicities were neutropenia, anemia, thrombocytopenia, nausea, dizziness, and fatigue. Single-agent-targeted therapy trials are feasible in BRCA+ patients. Given the rapid rate of accrual, profound response and favorable toxicity profile, the feasibility study was modified into a phase II study to determine pathologic complete response rates after 4–6 months of single-agent talazoparib.
28
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations
Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology · 2013 · 4.1K citations · Full text
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text
Medicine, Oncology, Pharmacology +17
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Jeff Hall, Ming K. Lee, Beth Newman et al. · Science · 1990 · 2.5K citations